Statin use and calcific uremic arteriolopathy: A matched case-control study

American Journal of Nephrology

Volumn 37, Issue 4, 2013, Pages 325-332

  Nigwekar, Sagar U ^a,c   Bhan, Ishir ^a   Turchin, Alexander ^d   Skentzos, Stephen C ^d   Hajhosseiny, Reza ^a   Steele, David ^a   Nazarian, Rosalynn M ^b   Wenger, Julia ^a   Parikh, Samir ^e   Karumanchi, Ananth ^e   Thadhani, Ravi ^a  

^a Division of Nephrology   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Calcific uremic arteriolopathy; Calciphylaxis; Case control; Statin; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CALCIUM; CINACALCET; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SERUM ALBUMIN; WARFARIN; ALBUMIN; ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; BODY REGIONS; CALCIFIC UREMIC ARTERIOLOPATHY; CALCINOSIS; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CAUCASIAN; CAUSE OF DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; INCIDENCE; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; AGED; HOSPITALIZATION; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MAINTENANCE THERAPY; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL;

CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SKIN DISEASES, VASCULAR; UREMIA; VASCULAR CALCIFICATION;

EID: 84875653503     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000348806     Document Type: Article

References (36)

1. Wilmer WA, Magro CM: Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15:172-186. (Pubitemid 41765928)
2. Brandenburg VM, Cozzolino M, Ketteler M: Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24:142-148.
3. Brandenburg VM, Kramann R, Specht P., Ketteler M: Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 2012; 27:1314-1318.
4. Nigwekar SU, Wolf M, Sterns R.H., Hix JK: Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3:1139-1143.
5. Nigwekar SU: An unusual case of nonhealing leg ulcer in a diabetic patient. South Med J 2007; 100:851-852. (Pubitemid 47356893)
6. Selye H, Gentile G, Prioreschi P: Cutaneous molt induced by calciphylaxis in the rat. Science 1961; 134:1876-1877.
7. Ross EA: Evolution of treatment strategies for calciphylaxis. Am J Nephrol 2011; 34:460-467.
8. Weenig RH: Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B. J Am Acad Dermatol 2008; 58:458-471.
9. Sowers KM, Hayden MR: Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3:109-121.
10. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al: Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol 2008; 179:1631-1636.
11. Kirmizis D, Papagianni A, Dogrammatzi F., et al: Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J Atheroscler Thromb 2010; 17:1256-1265.
12. Owens AP 3rd, Passam FH, Antoniak S, et al: Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122:558-568.
13. Son BK, Akishita M, Iijima K., Eto M, Ouchi Y: Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 2008; 15:63-68.
14. Weenig RH, Sewell LD, Davis M.D., McCarthy JT, Pittelkow MR: Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56:569-579. (Pubitemid 46400180)
15. Hayashi M, Takamatsu I, Kanno Y., et al: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27:1580-1584.
16. Mazhar AR, Johnson RJ, Gillen D, et al: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60:324-332. (Pubitemid 32587571)
17. Farah M, Crawford RI, Levin A, Chan Yan C: Calciphylaxis in the current era: emerging 'ironic' features? Nephrol Dial Transplant 2011; 26:191-195.
18. Nalichowski R, Keogh D, Chueh H.C., Murphy SN: Calculating the benefits of a Research Patient Data Repository. AMIA Annu Symp Proc 2006; 2006:1044.
19. Payne RB, Little AJ, Williams R.B., Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4:643-646.
20. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T: Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105:933-938. (Pubitemid 34184570)
21. Liao JK: Effects of statins on 3-hydroxy3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96:24F-33F. (Pubitemid 41207730)
22. Krane V, Wanner C: Statins, inflammation and kidney disease. Nat Rev Nephrol 2011; 7: 385-397.
23. Undas A, Brummel KE, Musial J, Mann K.G., Szczeklik A: Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253. (Pubitemid 32433713)
24. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-436. (Pubitemid 32097261)
25. Wanner C, Krane V, Marz W., et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. (Pubitemid 41058323)
26. Fellstrom BC, Jardine AG, Schmieder R.E., et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
27. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson D.W., Craig JC, Strippoli GF: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009:CD004289.
28. Baigent C, Landray MJ, Reith C, et al: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
29. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61:2210-2217. (Pubitemid 34546039)
30. Lund RJ, Andress DL, Amdahl M, Williams L.A., Heaney RP: Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31:165-170.
31. Teng M, Wolf M, Lowrie E., Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
32. Mizobuchi M, Finch JL, Martin D.R., Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72:709-715. (Pubitemid 47373790)
33. Galimberti RL, Farias Edos R, Parra IH, et al: Cutaneous necrosis by calcific uremic arteriolopathy. Int J Dermatol 2005; 44:101-106. (Pubitemid 40309135)
34. Llach F: Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am J Kidney Dis 1998; 32:514-518. (Pubitemid 28411229)
35. Holden RM, Booth SL: Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Prac Nephrol 2007; 3:522-523. (Pubitemid 47482715)
36. Holden RM, Clase CM: Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial 2009; 22:503-511.